Key Takeaways
- Science Corporation, founded by ex-Neuralink president Max Hodak, is preparing its first human trial in the US for a brain-computer sensor.
- Yale neurosurgery chair Dr. Murat Günel has joined as an adviser and will help lead the first human implant effort.
- Early trials will test a 520‑electrode sensor placed on top of the brain, not inserted into brain tissue.
- The long-term plan is a biohybrid interface combining lab-grown neurons with electronics to reduce tissue damage risk.
- Possible uses include recovery support after injury, seizure warning, and better monitoring for tumors and neurological disease.
What Science Corporation Is Building
Science Corporation, founded in 2021 by former Neuralink president Max Hodak, is preparing to begin its first human trials in the United States for a biohybrid brain-computer interface. The long-term ambition is to create a direct communication link between the brain and computers by combining lab-grown neurons with electronic components, rather than relying only on traditional metal electrodes.
The company argues that conventional brain implants can face durability and safety questions over time, especially if rigid probes irritate or damage tissue. Its biohybrid concept aims to use living neurons as part of the interface so the biological side can integrate more naturally with brain tissue while electronics handle recording and stimulation.
Why A Yale Neurosurgery Leader Joined the Project
Dr. Murat Günel, chair of neurosurgery at Yale School of Medicine, has joined Science Corporation as a scientific adviser after discussions that reportedly stretched over two years. He is expected to lead the effort to implant the company’s first sensor into a human brain, which adds clinical credibility and surgical leadership at a stage where device design meets real operating-room constraints.
For brain-interface startups, surgeon involvement is not a branding detail; it shapes the trial pathway. The way a device is positioned, secured, sterilised, and monitored can determine whether early safety data is clean enough to justify larger studies, and whether hospitals are willing to host future trials.
How The First Human Sensor Trial Will Work
The first human trials are expected to use an advanced version of the company’s sensor without embedded neurons. The device contains 520 recording electrodes in an area roughly the size of a pea, and the design choice is central to the risk profile: it will be placed on top of the brain, beneath the skull, rather than inserted into brain tissue.
That approach differs from systems that penetrate the cortex with threads or probes. By staying on the surface, the company believes it can reduce tissue damage risk and still capture useful brain signals, at least for early feasibility work focused on safety and basic performance.
What The Company’s Research and Funding Signal
Science Corporation reportedly raised $230 million in a Series C round, giving it a valuation of $1.5 billion, which indicates strong investor belief that its product roadmap can move from concept to regulated medical devices. The company’s most advanced product today is PRIMA, a vision restoration device for macular degeneration and related conditions, acquired in 2024 and advanced through clinical trials with plans to expand in Europe after regulatory approval.
On the brain-interface side, a 2024 working paper described safe implantation in mice and the ability to stimulate brain activity. The current engineering focus is refining prototypes and developing methods to grow neuron cells suitable for medical use, which is a major gating factor for any system that wants living tissue to be part of the implant.
What Applications and Timelines Look Realistic?
If the platform proves safe and functional, early medical use cases could include gentle electrical stimulation to support recovery in damaged brain or spinal cord tissue. More advanced applications could involve monitoring brain activity around tumors, providing early warnings for seizures, or developing new approaches to conditions such as Parkinson’s disease, where many current treatments manage symptoms rather than slowing progression.
The first trials are expected to involve patients already undergoing major brain surgery, such as stroke patients who need part of the skull removed, which creates an opportunity to place the sensor on the cortex during an existing procedure. Günel said it would be optimistic to expect human trials to begin in 2027, signalling that development work and regulatory discussions still have meaningful distance to cover.
